Suppliers and packagers for generic pharmaceutical drug: gefitinib

gefitinib

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Labs Fl Inc	GEFITINIB	gefitinib	TABLET;ORAL	208913	ANDA	Teva Pharmaceuticals, Inc.	0480-4053-56	30 TABLET, FILM COATED in 1 BOTTLE (0480-4053-56)	2023-06-21
Natco	GEFITINIB	gefitinib	TABLET;ORAL	212827	ANDA	Natco Pharma USA LLC	69339-168-03	30 TABLET, FILM COATED in 1 BOTTLE (69339-168-03)	2023-06-05
Qilu Pharm Hainan	GEFITINIB	gefitinib	TABLET;ORAL	211591	ANDA	Ingenus Pharmaceuticals, LLC	50742-366-30	30 TABLET, COATED in 1 BOTTLE (50742-366-30)	2023-04-27
Qilu Pharm Hainan	GEFITINIB	gefitinib	TABLET;ORAL	211591	ANDA	Qilu Pharmaceutical Co., Ltd.	67184-0531-1	30 TABLET, COATED in 1 BOTTLE (67184-0531-1)	2023-02-13
Qilu Pharm Hainan	GEFITINIB	gefitinib	TABLET;ORAL	211591	ANDA	Qilu Pharmaceutical Co., Ltd.	67184-0531-2	500 TABLET, COATED in 1 BOTTLE (67184-0531-2)	2023-02-13
Qilu Pharm Hainan	GEFITINIB	gefitinib	TABLET;ORAL	211591	ANDA	Qilu Pharmaceutical Co., Ltd.	67184-0531-3	3 BLISTER PACK in 1 CARTON (67184-0531-3) / 10 TABLET, COATED in 1 BLISTER PACK	2023-02-13
Astrazeneca	IRESSA	gefitinib	TABLET;ORAL	206995	NDA	AstraZeneca Pharmaceuticals LP	0310-0482-30	30 TABLET, COATED in 1 BOTTLE (0310-0482-30)	2015-07-13

Gefitinib Supply Chain Landscape

Last updated: February 19, 2026

This report analyzes the key suppliers and manufacturing capabilities for gefitinib, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and contract manufacturing organizations (CMOs) with significant roles in the global supply of gefitinib. Market concentration, geographic distribution, and potential supply chain risks are identified.

Who are the primary API manufacturers for gefitinib?

The production of gefitinib's active pharmaceutical ingredient (API) is concentrated among a select group of global manufacturers. These entities are critical to the drug's availability, and their production capacity and regulatory compliance directly impact market supply.

• AstraZeneca is the originator company and maintains significant manufacturing capabilities for gefitinib API. Their internal production is a cornerstone of the global supply.
• Indian API Manufacturers play a substantial role, driven by cost-effectiveness and established expertise in generic drug API production. Key players include:
  • Laurus Labs Limited: This company is recognized for its significant API manufacturing capacity and has been a supplier of gefitinib API. [1]
  • Divi's Laboratories Limited: Another prominent Indian API producer, Divi's has a broad portfolio and is a significant player in the global API market, potentially including gefitinib. [2]
  • Sun Pharmaceutical Industries Ltd.: As one of the largest pharmaceutical companies globally, Sun Pharma has extensive API manufacturing capabilities, which can encompass gefitinib for both branded and generic markets.
• Chinese API Manufacturers also contribute to the global supply, offering competitive pricing. While specific company names are often less publicly disclosed due to market dynamics, China is a major hub for API production. Companies operating under stringent Good Manufacturing Practices (GMP) standards are key suppliers.

What are the key regulatory considerations for gefitinib API suppliers?

API suppliers for gefitinib must adhere to stringent regulatory requirements enforced by major health authorities. Compliance ensures product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes stringent controls over manufacturing processes, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API information without disclosing proprietary details to the drug product manufacturer.
• Inspections and Audits: Suppliers are subject to regular inspections by regulatory authorities and audits by their pharmaceutical clients. Successful audits are critical for maintaining supply agreements.
• Impurity Profiling and Control: Rigorous control and monitoring of impurities are essential. Regulatory bodies have specific guidelines regarding acceptable impurity levels, including genotoxic impurities.
• Supply Chain Security and Traceability: Increasing regulatory focus is placed on ensuring the security and traceability of the pharmaceutical supply chain to prevent counterfeiting and ensure product integrity from API source to finished drug product.

Which Contract Manufacturing Organizations (CMOs) are involved in gefitinib production?

While API manufacturing is a distinct step, the formulation and finished dosage form production of gefitinib often involve CMOs, particularly for generic manufacturers entering the market.

• Generic Drug Formulators: CMOs specializing in the formulation of oral solid dosage forms (tablets) are crucial for generic gefitinib products. They handle granulation, blending, compression, and coating processes.
• Key CMO Regions:
  • India: Numerous Indian CMOs possess the capacity and regulatory approvals to manufacture finished gefitinib tablets. Their cost-effectiveness makes them attractive partners for generic drug companies.
  • Europe: European CMOs offer high-quality manufacturing services, often catering to more established markets with stringent regulatory requirements.
  • North America: While less common for cost-sensitive generics, some North American CMOs provide specialized services or are preferred by companies seeking domestic manufacturing.
• Specific CMO Capabilities: CMOs offering gefitinib manufacturing typically have expertise in:
  • Tablet Manufacturing: High-speed tablet presses, advanced granulation techniques, and sophisticated coating capabilities.
  • Analytical Testing: Comprehensive in-house testing for dissolution, potency, uniformity, and stability.
  • Packaging: Blister packing, bottle filling, and secondary packaging compliant with regional labeling requirements.
• Supplier Qualification: Pharmaceutical companies rigorously qualify CMOs based on their regulatory track record, quality systems, production capacity, and cost competitiveness.

What is the geographic concentration of gefitinib API manufacturing?

The manufacturing of gefitinib API is geographically concentrated, with significant production hubs in Asia, particularly India and China. This concentration presents both opportunities for cost efficiency and potential risks related to supply chain disruptions.

• India: Represents a dominant force in global API manufacturing, including for oncology drugs like gefitinib. Its large number of GMP-certified facilities, skilled workforce, and competitive pricing make it a primary sourcing region.
• China: Is another major global API manufacturing center. Chinese manufacturers offer significant capacity and are a key source for many APIs, including those used in gefitinib production.
• Europe and North America: While these regions have advanced pharmaceutical manufacturing capabilities, the production of high-volume APIs like gefitinib for generic markets is less concentrated due to higher operating costs compared to Asian counterparts. However, some specialized or niche API production may occur.

Table 1: Key Geographic Regions for Gefitinib API Manufacturing

Region	Primary Role in API Production	Key Strengths	Potential Risks
India	High volume production	Cost-effectiveness, large capacity, regulatory experience	Geopolitical instability, regulatory changes, IP concerns
China	High volume production	Cost-effectiveness, broad manufacturing base	Quality control variations, supply chain transparency, trade disputes
Europe	Niche/Specialty production	High quality standards, advanced technology	Higher cost of production
North America	Limited API production	Advanced technology, IP protection	Higher cost of production

What are the potential supply chain risks for gefitinib?

The global nature of gefitinib production exposes its supply chain to various risks that could impact availability and pricing.

• Geopolitical Instability: Tensions or conflicts in key manufacturing regions (e.g., India, China) can disrupt production and logistics.
• Regulatory Changes: New or stricter regulations concerning API quality, environmental impact, or import/export policies in major producing countries can lead to supply interruptions or increased costs.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can halt manufacturing operations and disrupt transportation networks.
• Intellectual Property Disputes: While the primary patents for gefitinib have expired in many regions, ongoing IP disputes related to manufacturing processes or specific formulations can create uncertainty.
• Raw Material Sourcing: The synthesis of gefitinib relies on various chemical intermediates. Disruptions in the supply of these upstream raw materials, often sourced from different global suppliers, can impact the final API production.
• Quality Control Issues: A single instance of significant quality non-compliance at a major API manufacturing site can lead to product recalls, regulatory actions, and a sudden shortage of the drug.
• Logistics and Transportation: Reliance on global shipping and air freight makes the supply chain vulnerable to port congestion, shipping container shortages, and rising transportation costs.
• Counterfeiting: The global supply chain for pharmaceuticals is susceptible to counterfeiting. Robust anti-counterfeiting measures are essential to protect patient safety.

What is the competitive landscape for generic gefitinib?

The expiration of key patents for gefitinib has opened the market to generic competition, leading to increased market fragmentation and price pressure.

• Originator Brand: AstraZeneca's Iressa® remains a significant player, but its market share is challenged by generics.
• Generic Manufacturers: A growing number of pharmaceutical companies, particularly from India and China, have launched generic versions of gefitinib. These companies compete primarily on price and market access.
• Regulatory Approvals: Generic manufacturers must secure approvals from regulatory agencies in each target market. This involves demonstrating bioequivalence to the reference product and meeting all quality and manufacturing standards.
• Pricing Strategies: Generic competition has driven down the price of gefitinib significantly. Manufacturers employ aggressive pricing strategies to gain market share.
• Market Access: Gaining formulary access and preferred provider status with healthcare systems and insurance providers is crucial for generic success.

How do manufacturing costs influence the gefitinib supply chain?

Manufacturing costs are a primary driver for the global supply chain of gefitinib, especially for generic production.

• API Synthesis Costs: The chemical synthesis of gefitinib API involves multiple steps, each with associated costs for raw materials, labor, energy, and waste disposal.
• Labor Costs: Significant cost differentials exist between manufacturing hubs in Asia (India, China) and Western countries, influencing where API and finished product manufacturing is concentrated.
• Regulatory Compliance Costs: Adhering to GMP standards, maintaining quality systems, and undergoing inspections incur substantial costs for manufacturers. These costs are often higher in more developed regulatory environments.
• Economies of Scale: Large-scale API production facilities can achieve lower per-unit costs due to economies of scale. This incentivizes consolidation among API suppliers.
• Raw Material Fluctuations: The cost of key starting materials and intermediates used in gefitinib synthesis can fluctuate based on global supply and demand, impacting overall API production costs.
• Finished Dosage Form (FDF) Manufacturing: Costs associated with tablet compression, coating, packaging, and quality control for the final drug product also vary by region and the specific CMO utilized.

Key Takeaways

• Gefitinib API manufacturing is primarily concentrated in India and China, with AstraZeneca also maintaining internal production capabilities.
• Laurus Labs and Divi's Laboratories are notable Indian API suppliers.
• Stringent adherence to GMP and the submission of Drug Master Files are critical regulatory requirements for all API suppliers.
• Contract Manufacturing Organizations (CMOs), particularly in India, play a significant role in the formulation and packaging of generic gefitinib finished dosage forms.
• Supply chain risks include geopolitical instability, regulatory changes, natural disasters, quality control failures, and raw material sourcing issues.
• The generic gefitinib market is highly competitive, characterized by price pressure and a focus on market access and regulatory approvals.
• Manufacturing costs, driven by labor, raw materials, and regulatory compliance, heavily influence the geographic concentration and sourcing strategies within the gefitinib supply chain.

Frequently Asked Questions

1. What are the critical raw materials for gefitinib API synthesis? The synthesis of gefitinib involves complex multi-step chemical processes. Key intermediates and reagents include substituted anilines, quinazoline derivatives, and various catalysts and solvents. Specific detailed precursors are proprietary information within the manufacturing process.
2. How does the patent expiry of gefitinib impact its supply chain? Patent expiry allows for the entry of generic manufacturers, increasing the number of API and finished drug product suppliers. This typically leads to greater supply chain diversity but also intensifies competition and price pressures.
3. What are the primary quality control measures for gefitinib API? Quality control for gefitinib API includes testing for identity, purity (using techniques like HPLC), assay (potency), residual solvents, heavy metals, and specific process-related impurities. Stability studies are also conducted to determine shelf-life.
4. Are there any significant differences in quality between gefitinib APIs from different manufacturers? While all API manufacturers must comply with GMP, variations in specific manufacturing processes can lead to subtle differences in impurity profiles or crystal forms. Regulatory bodies require that all APIs meet compendial standards and approved specifications, ensuring therapeutic equivalence.
5. What is the typical lead time for sourcing gefitinib API from major suppliers? Lead times for gefitinib API can vary widely depending on the supplier's current production schedule, order volume, and existing inventory. Generally, large-scale orders may require lead times of several months to ensure production and quality assurance.

Citations

[1] Laurus Labs Limited. (n.d.). API Products. Retrieved from https://www.lauruslabs.com/products/api-products/ [2] Divi's Laboratories Limited. (n.d.). Products. Retrieved from https://www.divislabs.com/products/